See more : Trakcja S.A. (TRK.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reviva Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Garden Stage Limited Ordinary Shares (GSIW) Income Statement Analysis – Financial Results
- SBI Holdings, Inc. (8473.T) Income Statement Analysis – Financial Results
- ACON Holding Inc. (3710.TWO) Income Statement Analysis – Financial Results
- Mallard Acquisition Corp. (MACU) Income Statement Analysis – Financial Results
- WiseTech Global Limited (WTCHF) Income Statement Analysis – Financial Results
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 724.74K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -724.74K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31,419.82B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| General & Administrative | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 39,503.64B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Income | 0.00 | 182.80K | 0.00 | 105.18K | 201.00 | 0.00 |
| Interest Expense | 0.00 | 182.80K | 2.41K | 1.45M | 469.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |
| EBITDA | -39,503.64B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39,503.64B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 39,503.60B | -11.91K | 1.59M | -1.35M | -469.17K | -557.68K |
| Income Before Tax | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Net Income | -39,260.84B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| EPS Diluted | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| Weighted Avg Shares Out | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
Source: https://incomestatements.info
Category: Stock Reports